Extracorporeal Cardiopulmonary Resuscitation-Where Do We Currently Stand?

Extracorporeal cardiopulmonary resuscitation (eCPR) is a method of acute resuscitation for patients who have suffered a cardiac arrest through the utilization of an extracorporeal membrane oxygenation (ECMO) pump. The use and efficacy of eCPR is an active area of investigation with ongoing clinical investigation across the world. Since its inception, ECMO has been utilized for several conditions, but more recently, its efficacy in maintaining cerebrovascular perfusion in eCPR has generated interest in more widespread utilization, particularly in cases of out-of-hospital cardiac arrest.

Methylene blue at recommended concentrations alters metabolism in early zebrafish development.

Methylene blue (MB) is an antifungal agent widely used during critical stages of zebrafish development. Most guidelines recommend 0.00005% or 0.

A Clinical Practice-Based Comparison of Conventional and Individualized Dosing Strategies for Therapeutic Enoxaparin.

To understand differences in anti-factor-Xa levels produced by two different dosing strategies (conventional and individualized) for therapeutic enoxaparin in a cohort of hospital inpatients. A multicenter, retrospective cohort study over a two- and a half-year period for inpatients with stable renal function and on therapeutic enoxaparin. Anti-factor-Xa levels were taken 3-5 h after enoxaparin administration and a minimum of 48 h of dosing.

Origins and Distribution of Panicum Mosaic Virus and Sugarcane Mosaic Virus on in Australia.

is a premium turf grass in warm temperate and subtropical regions of the world and is the most important turf species in Australia based on the value of its production. A new disease called buffalo grass yellows (BGY) has become a problem on turf farms in Australia. We surveyed turf farms in New South Wales (NSW), Queensland (Qld) and Western Australia to determine whether panicum mosaic virus (PMV) and sugarcane mosaic virus (SCMV) were associated with BGY.

First-in-Human Phase 1 study of a CD16A bispecific innate cell engager, AFM24, targeting EGFR-expressing solid tumors.

Purpose: Innate immune cell-based therapies have shown promising antitumor activity against solid and hematologic malignancies. AFM24, a bispecific innate cell engager, binds CD16A on natural killer (NK) cells/macrophages and EGFR on tumor cells, redirecting antitumor activity towards tumors. The safety and tolerability of AFM24 was evaluated in this Phase 1/2a dose escalation/dose expansion study in patients with recurrent or persistent, advanced solid tumors known to express EGFR.